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Probing the metabolic phenotype of breast cancer cells by 
multiple tracer Stable Isotope Resolved Metabolomics
Andrew N. Lanea,b,c,d,*, Julie Tana,e, Yali Wanga,f, Jun Yana, Richard M. Higashib,c,d, and 
Teresa W.-M. Fana,b,c,d,*
aJ.G. Brown Cancer Center, University of Louisville, Louisville, KY
bDept. Chemistry and Center for Regulatory and Environmental Analytical Metabolomics, 
University of Louisville, Louisville, KY
Abstract
Breast cancers vary by their origin and specific set of genetic lesions, which gives rise to distinct 
phenotypes and differential response to targeted and untargeted chemotherapies. To explore the 
functional differences of different breast cell types, we performed Stable Isotope Resolved 
Metabolomics (SIRM) studies of one primary breast (HMEC) and three breast cancer cells 
(MCF-7, MDAMB-231, and ZR75-1) having distinct genotypes and growth characteristics, 
using 13C6-glucose, 13C-1+2-glucose, 13C5,15N2-Gln, 13C3-glycerol, and 13C8-octanoate as 
tracers. These tracers were designed to probe the central energy producing and anabolic pathways 
(glycolysis, pentose phosphate pathway, Krebs Cycle, glutaminolysis, nucleotide synthesis and 
lipid turnover). We found that glycolysis was not associated with the rate of breast cancer cell 
proliferation, glutaminolysis did not support lipid synthesis in primary breast or breast cancer 
cells, but was a major contributor to pyrimidine ring synthesis in all cell types; anaplerotic 
pyruvate carboxylation was activated in breast cancer versus primary cells. We also found that 
glucose metabolism in individual breast cancer cell lines differed between in vitro cultures and 
tumor xenografts, but not the metabolic distinctions between cell lines, which may reflect the 
influence of tumor architecture/microenvironment.
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1. Introduction
Breast cancer continues to be a major disease afflicting 290,000 people every year in the US, 
of which ca. 40,000 died (ACS 2016). Although in recent years, improved surgical 
techniques, diagnostic procedures and targeted therapeutics such as trastuzumab and 
antiestrogen treatment have significantly improved the overall survival rates for those 
patients who can benefit (Hudis 2007) (Bliss, Kilburn et al. 2012), recurrence remains a 
problem. In addition, some forms of breast cancer are refractory to treatment, in particular 
the triple negative breast cancers and BRCA1 and 2 breast cancers. As with many cancers, 
5-year survival rates decrease markedly with increasing stages as the options for treatment 
become limited (ACS 2016).
Although numerous genetic lesions that are responsible for the development of various 
subtypes of breast cancers have been identified, for example BRCA1,2, HER2/neu, among 
many others (Stephens, Tarpey et al. 2012), the underlying genetics describes only part of 
the problem, and is therefore insufficient from the diagnostic and treatment standpoints 
(Graur, Zheng et al. 2013). Cancers are also metabolic diseases, as the metabolic activity of 
transformed cells is altered to provide advantages in growth, survival and metastasis (Fan, 
Lane et al. 2009, Vander Heiden, Cantley et al. 2009, Linehan, Srinivasan et al. 2010, Le, 
Lane et al. 2012, Liu, Le et al. 2012, Marin-Valencia, Cho et al. 2012, Yuneva, Fan et al. 
2012). Metabolic reprogramming is now regarded as one of the hallmarks of cancer 
(Hanahan and Weinberg 2011). Although the set of genetic lesions, the origin of the 
transformed cells, and their microenvironment differ among cancer cells (Fan, Lane et al. 
2009, Marin-Valencia, Yang et al. 2012, Giussani M., Merlino G. et al. 2015), their 
metabolism is generally enhanced to provide sufficient metabolic energy and anabolic 
substrates to drive proliferation, which requires macromolecular biosynthesis. Often, cancer 
cell metabolism is also adapted to deal with an increasingly hostile extracellular (Gatenby 
and Gillies 2008) and intracellular environments, including ROS production from 
accelerated respiration (Fantin, St-Pierre et al. 2006, Telang 2007, Strovas, McQuaide et al. 
2010, Weinberg, Hamanaka et al. 2010, Koppenol, Bounds et al. 2011).
An especially well-attested metabolic adaptation in cultured cancer cells and in tumors is 
accelerated lactic fermentation even in the presence of oxygen, the so-called Warburg effect. 
This results not only in increased glucose uptake, but also a diversion of the glycolytically 
produced pyruvate to lactate, and the co-export of the lactate with a proton, thereby 
acidifying the extracellular compartment (Tannock and Rotin 1989, Gillies and Gatenby 
2007). Nevertheless, a significant fraction of the consumed glucose is used anabolically, 
including synthesis of hexose derivatives (Moseley, Lane et al. 2011), nucleotides and 
nucleic acids biosynthesis (via the pentose phosphate pathway, the pyrimidine pathway via 
glucose-and glutamine-derived aspartate (Fan, Tan et al. 2012, Lane and Fan 2015) the 
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purine pathway via glucose derived serine, glycine, and one-carbon metabolism (Lee, Boros 
et al. 1998, Kominsky, Klawitter et al. 2009, Possemato, Marks et al. 2011, Fan, Tan et al. 
2012, Locasale 2013, Labuschagne, van den Broek et al. 2014, Lane and Fan 2015), 
complex lipid biosynthesis (Swinnen, Brusselmans et al. 2006, Lane, Fan et al. 2009, 
Metallo, Gameiro et al. 2011), and protein synthesis (cf. Figure 1). Moreover, glucose is 
metabolized in the mitochondrial Krebs cycle as mitochondria remain active in many cancer 
cells, and in fact may respire at a higher rate than the untransformed cell counterparts 
(Telang 2007, Strovas, McQuaide et al. 2010). The respiratory activity is often, though not 
always perfectly, coupled to ATP synthesis (Gogvadze, Zhivotovsky et al. 2009) to 
supplement glycolytically-derived energy. Mitochondria of cancer cells are also active in 
oxidizing substrates other than glucose-derived pyruvate, notably glutamine (Yuneva, 
Zamboni et al. 2007, DeBerardinis and Cheng 2010) and in certain circumstances, fatty 
acids (Guppy, Leedman et al. 2002). As Figure 1 shows, the ultimate fate of the glutamine 
carbon is variable (Mazurek and Eigenbrodt 2003, DeBerardinis and Cheng 2010, Fan, Tan 
et al. 2012, Le, Lane et al. 2012), though the amide nitrogen is used in nucleobase synthesis, 
in the hexosamine pathway, or excreted as ammonium ions via glutaminase activity 
(DeBerardinis and Cheng 2010, Lane and Fan 2015).
Although glucose is generally the preferred carbon source for growth and survival for cancer 
cells by supporting glycolysis and the pentose phosphate pathway, Gln is also important by 
providing both carbon and nitrogen for pyrimidine and purine biosynthesis. Both of these 
substrates along with serine, glycerol and fatty acids may also be used for lipid biosynthesis. 
Here we report the use of multiple stable isotope tracers and SIRM to compare the fates of 
different carbon sources for lipid and central metabolism in estrogen-sensitive breast cancer 
cells, a triple negative breast cancer cell, and an untransformed human mammary epithelial 
cells (HMEC). These 13C-enriched carbon sources helped delineate specific metabolic 
pathways that are central to proliferation, and therefore enabled understanding of the 
metabolic basis for differential proliferation among the cell types.
2. Materials and Methods
2.1 Materials
Established cancer cell lines (Table 1) were purchased from ATCC. Primary HMEC cells 
were obtained from Lonza.
Isotopically enriched precursors, [U-13C]-glucose, [13C-1], [13C-2] glucose, [U-13C,15N]-
glutamine, [U-13C]-octanoate and [U-13C]-glycerol were purchased from Sigma Isotec (St. 
Louis, MO), and were at >99% isotope purity.
2.2 Cell growth and growth curves
Cells were cultured in RPMI containing 5.5 mM glucose + 4 mM Gln in which either the 
glucose contained 13C at all or specific position (C1 or C2) or the glutamine contained 13C 
and 15N at all positions. When present, [U-13C]-octanoate or [U-13C]-glycerol were added to 
a final concentration of 2 mM in the cell media. Cell growth was monitored by trypan blue 
exclusion and counting viable cells.
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2.3 Mouse Xenografts
NOD/SCID Gamma (NSG) mice were obtained from Jackson Laboratories (Bar Harbor, 
Maine), were caged and fed according to the University of Louisville IACUC. Orthotopic 
xenografts were achieved by injecting cells at 1–10 million per mL in matrigel directly into 
the mammary fat pad of female mice in groups of 5. For estrogen-dependent cells, estradiol 
was supplied to the mice.
Once tumors reached a size of 0.5 to 1 cm, the mice were injected via the tail vein with 
either [U-13C]-glucose or [U-13C,15N]-glutamine 3 times with a spacing of 15 minutes, as 
previously described (Fan, Lane et al. 2011, Lane, Yan et al. 2015). At 1 and 45 minutes 
after the first injection, blood samples were taken introrbitally, placed into K2-EDTA tubes 
and allowed to stand for 1 minute at room temperature before being chilled on ice. The 
blood was then separated into plasma and packed cells by centrifugation at 3500 g for 15 
min at 4 °C. Plasma was aspirated and flash frozen in liq. N2 for subsequent analysis. The 
mice were then sacrificed by cervical dislocation, and the tumors excised and flash frozen in 
liquid nitrogen. Lung, liver, heart, kidney and brain were sequentially dissected and also 
flash frozen in liquid nitrogen for metabolic analysis (Fan, Lane et al. 2011, Lane, Yan et al. 
2015).
2.4 Metabolite extractions
Media at different time points were sampled and flash frozen for subsequent extraction using 
trichloracetic acid (Fan, Kucia M. et al. 2008) and analysis by NMR. Cells were quenched 
and extracted with 10% ice-cold trichloroacetic acid or acetonitrile:H2O:chloroform 
(2:1.5:1, v/v) as previously described (Fan 2010, Fan 2012). To calculate the relative 
consumption of 13C glucose and 13C and 12C lactate production, 100 μL aliquots of the 
media at t=0 and t=24 h were extracted and analyzed by 1H NMR, which distinguishes 13C 
and 12C lactate isotopomers (Lane and Fan 2007). Glucose was quantified from the H1a 
resonances, and the lactate from the C3H resonances. The amount of glucose consumed or 
lactate produced was calculated as the difference in glucose or lactate content in the media 
between zero and 24 h. The fraction of glucose consumed that was converted to 13C lactate, 
FGlc ○ Lac was calculated as: ,
(1)
The fractional enrichment of lactate, fLac was calculated as
(2)
as previously described (Lane and Fan 2007, Lane, Fan et al. 2008, Lane, Fan et al. 2009, 
Lane 2012, Fan and Lane 2016). In these experiments, cells were seeded at the same density. 
The amount of valine consumption over the experimental period was determined to be 
Lane et al. Page 4
Metab Eng. Author manuscript; available in PMC 2018 September 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
negligible compared with glucose and lactate, and thus was used as an internal concentration 
standard.
For the cells, both polar and non-polar (lipids) were analyzed by high resolution NMR and 
Fourier transform-ion cyclotron resonance-mass spectrometry (FT-ICR-MS).
2.5 Mass Spectrometry
Ultra high-resolution mass spectra were recorded by direct nanoelectrospray infusion on a 
Thermo LTQ-FT ICR-MS interfaced to an Advion Nanomate ESI at a resolution of 400,000 
at m/z of 200 Da. Data were processed and assigned as previously described (Lane, Fan et 
al. 2008, Higashi, Fan et al. 2014).
2.6 NMR spectroscopy
NMR spectra were recorded at 14.1 T or 18.8 T on Varian Inova spectrometers at 293 K and 
compounds were identified and quantified as previously described (Fan and Lane 2008, Fan 
and Lane 2012).
1D 1H NMR spectra were recorded with an acquisition time of 2 s and a relaxation delay of 
3 s during which the residual HOD resonance was suppressed using a weak transmitter 
pulse. The FIDs were zero filled to 128 k points, and apodized using an unshifted Gaussian 
and a 0.5 Hz line broadening exponential function. 1D HSQC spectra were recorded with an 
acquisition time of 0.15 s and a relaxation delay of 1.35 s with GARP decoupling. The FIDs 
were zerofilled to 8192 points and apodized using an unshifted Gaussian and a 4 Hz line 
broadening exponential. TOCSY spectra were recorded with an acquisition time of 0.5 s in 
t2 and 0.05 s in t1. The data table was zerofilled to 8192 by 2048 points, and apodized using 
an unshifted Gaussian and a line broadening exponential of 1 Hz in both dimensions. 
2D 1H{13C}-HSQC were recorded with an acquisition time of 0.15 s in t2 and 0.0125 s in t1. 
Data in t1 were linear predicted once and zerofilled to 2028 points, and apodized using an 
unshifted Gaussian plus a line broadening exponential of 4 Hz in t1, and 1 Hz in t2.
Spectra were referenced to DSS, which also served as a concentration standard.
Quantitative isotopomer distributions in metabolites were determined of both polar and non-
polar (lipid) extracts by 1 and 2D NMR spectra as previously described (Lane and Fan 2007, 
Lane, Fan et al. 2008, Lane, Fan et al. 2009, Lane 2012, Fan and Lane 2016).
3. Results
We have investigated the utilization of different substrates in three breast carcinoma and one 
primary breast cell lines under standardized growth conditions. These cell lines have 
different doubling rates and dependence on estradiol (Table 1).
3.1. 13C6-glucose reveals differential capacity of glycolysis and glucose consumption 
among breast cell lines
The four breast cancer cell lines were grown in 13C6-glucose (Glc) for 24 h before the polar 
extracts of both cells and media were analyzed by 1H NMR.
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Table 2 compares the normalized amounts of 13C6-Glc consumed, 13C3-lactate (Lac) 
released, and fractional conversion of 13C6-Glc to 13C3-Lac (FGlc ○ Lac) in the media. The 
FGlc ○ Lac ranged from 0.28 to 0.62, with ZR-75-1 showing the highest value, which 
together with the highest 13C3-Lac release in the medium suggested that the slow-growing 
ZR-75-1 had the highest glycolytic capacity among the four cell lines. It is also interesting to 
note that the fastest growing MDA-MB231 were similar to the primary HMEC in terms of 
FGlc ○ Lac and 13C3-Lac release into the medium, which indicated that glycolytic capacity 
was not always linked to proliferation rates. Furthermore, 1H NMR analysis readily 
quantified both 13C labeled and unlabeled lactate (12C3-Lac), which showed that the MDA-
MB-231 had lower extent of 12C3-Lac release relative to HMEC and ZR-75-1 cells (Table 
2). This result suggested that HMEC and ZR75-1 produced more lactate from sources other 
than glucose (Lane, Fan et al. 2011). However, this lactate production did not involve 
classical glutaminolysis since little 13C-Lac was derived from 13C-glutamine (data not 
shown).
3.3 Breast cell lines exhibit differential capacity for oxidative and non-oxidative branches 
of the pentose phosphate pathway (PPP)
Proliferating cells require active pentose phosphate pathway (PPP) to supply ribose-5-
phosphate (R5P) for the synthesis of nucleotides, DNA, and RNA. The operation of PPP was 
demonstrated in the four cell lines with the use of 13C6-glucose, which showed the 
expected 13C incorporation into the ribose moiety of different nucleotides (Figure 2).
Volume integration of the central 12C and 13C satellite cross-peaks provided the 
fractional 13C enrichment (Lane and Fan 2007) in the ribosyl unit of adenine (AXP) and 
uracil (UXP) nucleotides at the 1′ position. These values differed among the four cell lines 
with the slow growing ZR75-1 having the lowest values for both AXP and UXP among the 
four cell lines, which could point to a lower PPP capacity for ZR75-1 than for the other three 
cell lines. Alternatively, ZR75-1 may derive its ribose from non-glucose source(s) and/or 
have a lower capacity for nucleotide synthesis.
The PPP can also supply NADPH for fatty acid biosynthesis (see below) and redox 
homeostasis via glutathione metabolism. However, the PPP generates NADPH only via the 
oxidative and not the non-oxidative branch. The relative contribution of these two branches 
of PPP is not readily delineated using 13C6-glucose as tracer. We thus investigated the 
capacity for these two branches of PPP using an equimolar mixture of 13C-1- and 13C-2- 
glucose tracers with 2D 1H TOCSY NMR analysis of the positional isotopomers in the 
ribose rings of purine and pyrimidine nucleotides. If only the oxidative branch (Ox PPP) is 
operative, then the 13C1 atom would be lost as 13CO2, and 13C2 would be incorporated 
into 13C1′ (●) of the nucleotide riboses (Figure 3), resulting in a pair of horizontal 13C 
satellite cross-peaks for UXP-1′ and AXP-1′ in the TOCSY spectra (Figure 4). In contrast, 
if the non-oxidative branch of the PPP (NOx PPP) is active, then the ribose labeling patterns 
become more complex, as 13C labels at C1 or C2 positions of glucose is metabolized into 
F6P at C1 or C2 and GAP at C2 or C3 via glycolysis, followed by 13C scrambling (●) when 
GAP is incorporated into the intermediates of PPP including F6P, Sed7P, R5P, and X5P via 
the reversible reactions of transketolase (TK), transaldolase (TA). Further metabolism of 
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R5P via nucleotide synthesis and F6P via glycolysis results in 13C labels respectively at C1′ 
to C5′ position of the ribose subunit of nucleotides as well as at C1 to C3 position of lactate 
and Ala (Figure 3).
Figure 4 showed strong 13C enrichment at C2′ of AXP/UXP (vertical pair of 13C satellites 
for the C1′-2′ cross-peaks) and to a lesser extent at C3′ of AXP (vertical pair of 13C 
satellites for the C1′-3′ cross-peak), in addition to the intense C1′ of AXP and UXP 
(horizontal pair of 13C satellites for the C1′-2′/C1′-3′ cross-peaks) in HMEC, MCF7, and 
MDAMB-231 cells. This demonstrates that the NOx PPP was active as 13C labels in C2′ 
and C3′ of ribose can only be derived from 13C-1- + 13C-2-glucose via NOx PPP (cf. Figure 
3). By quantifying the fractional enrichment (F) at C1′ and C2′ of the ribose units of AXP 
and UXP via the central 12C and 13C satellite cross-peaks (Fan, Tan et al. 2012), we 
determined that the ratio of F1′AXP to F2′AXP or F1′UXP to F2′UXP was higher in the 
carcinoma MCF7 and MDAMB-231 than the primary HMEC cell lines (Table 3). This result 
suggested that Ox PPP was relatively more active than NOx PPP in the cancer versus the 
primary breast cell lines, thereby contributing to more NADPH production in the former. We 
further noted that the 13C labeling at C2 (vertical pair of 13C satellites, Figure S1) was 
relatively more extensive than that at C3 (horizontal pair of 13C satellites, Figure S1) of 
lactate and Ala in HMEC versus MCF7 and MDAMB-231 cell lines, which pointed to 
relatively higher PPP than glycolytic capacity in HMEC compared with the two cancer cell 
lines. This is because Ox PPP operation would lead to the loss of C3 labels while NOx PPP 
contributed to C2 labels of lactate and Ala (Figure 3), thereby leading to selective 13C 
enrichment at C2 of these two metabolites in HMEC cells. The absolute fluxes through the 
branches of the PPP have not been determined in these experiments, which also requires a 
full accounting of the carbon flow into the excreted lactate and alanine.
3.3. Both glucose and glutamine fuel Krebs cycle and pyrimidine biosynthesis
Both glucose and Gln can be metabolized through the Krebs cycle to produce Asp, which is 
the precursor to pyrimidine ring synthesis (Figure 5).
We investigated these pathways by 2D 1H TOCSY analysis, which revealed the 13C labeling 
patterns of uracil rings in UXP of three breast cell lines grown in 13C6-glucose or 13C5,15N2-
Gln. As shown in Figure 6 and Table 4, 13C atoms from both tracers were incorporated into 
the uracil ring at C5 and/or C6 in HMEC, MCF7, and ZR75-1 cells. 13C5,15N2-Gln 
contributed more substantially to these uracil carbons than 13C6-Glc in HMEC and ZR75-1 
cells as we have observed previously for lung cancer cells (Fan, Tan et al. 2012). However, 
the opposite was evident for MCF7 cells. In addition, MCF7 and ZR75-1 cells showed a 
higher fractional enrichment in 13C6-Glc-derived uracil at C5,6 than HMEC. This 13C 
isotopomer is likely to be produced from the anaplerotic pyruvate carboxylation (PC) 
pathway, as shown in Figure 5 (denoted by ●) (Le, Lane et al. 2012, Sellers, Fox et al. 
2015). Thus, the two anaplerotic pathways involving PC and glutaminolysis may be 
differentially utilized by different breast cell lines.
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3.4 Phospholipid biosynthesis differs among breast cell lines and sources
In addition to providing Asp for pyrimidine ring synthesis, glucose or Gln metabolism via 
the Krebs cycle supplies citrate as precursor for phospholipid biosynthesis, which is required 
for cell proliferation. Thus, the critical enzymes of fatty acid biosynthesis are commonly up 
regulated in cancer cells (Kuhajda 2000, Vazquez-Martin, Colomer et al. 2008, Daniëls VW., 
Smans K. et al. 2014). We have previously shown extensive de novo synthesis of complex 
lipids from glucose in the tamoxifen-resistant MCF-7 variant LCC2 cell line (Lane, Fan et 
al. 2009). Here, we compared 13C incorporation from 13C6-glucose into 
glycerophospholipids of HMEC, MCF-7 (Figure 7A,B), and ZR75-1 (Figures 8A) versus the 
faster growing MDA-MB-231 cells (Figures 7C). Both glycerol backbone and fatty acyl 
chains of PLs were strongly labeled in HMEC, MCF-7, and ZR75-1 cells grown in the 
presence of 13C6-glucose. The 13C satellite cross-peak patterns of the glycerol backbone 
(peaks 2, 4, 5, 8, and 10, Fig. 7) indicated the presence of the 13C3-isotopomer species only, 
which is consistent with its synthesis from dihydroxyacetone-3-phosphate (DHAP) in the 
glycolytic pathway. The 13C-labels in the fatty acyl chains were presumably derived 
from 13C-acetyl CoA, generated from citrate via the action of ATP-dependent citrate lyase in 
the cytoplasm. In contrast, the MDAMB-231 cells were significantly 13C labeled only in the 
glycerol backbone (ca. 25–30% enrichment), despite the much faster cell proliferation rate 
(Table 1). This suggested an alternative source of fatty acids such as internal lipid droplets.
In addition to glucose, glutamine can be used for lipid synthesis via reductive carboxylation 
under certain conditions (Frezza, Zheng et al. 2011, Mullen, Wheaton et al. 2011, Yang, 
Lane et al. 2013) and/or malic enzyme action (Le, Lane et al. 2012). Fig. 8B shows the low 
incorporation of glutamine carbon into the lipid pool, at either the fatty acyl chains or the 
glycerol backbone in ZR75-1 cells, whereas glucose carbon was extensively incorporated 
into both subunits. Neither were glutamine carbons significantly incorporated into the lipids 
of HMEC, MDAMB-231, or MCF-7 cells (data not shown). We estimated from the TOCSY 
spectra that at most 5% of the C2,3,4 or terminal CH3 of the acyl chains was derived 
from 13C5-Gln, which was much lower than the extent of incorporation of either 13C6-
glucose (ca. 60%) or 13C8-octanoate carbons (ca. 30%), indicating that glucose or 
exogenous fatty acids was preferred over Gln for the synthesis of intact lipid. This differed 
from the case for the free fatty acid pool, where reductive carboxylation has been shown to 
contribute significantly to the de novo synthesis of this pool under some conditions (Frezza, 
Zheng et al. 2011, Mullen, Wheaton et al. 2011, Yang, Lane et al. 2013).
Moreover, 13C3-glycerol was a good substrate for the glycerol backbone of lipids in ZR75-1 
cells (13C enrichment = 20–25%), but not for the fatty acyl chains, whereas the opposite was 
observed for 13C8-octanoate. The lack of 13C incorporation from 13C8-octanoate into the 
glycerol backbone was as expected as fatty acids are not gluconeogenic substrates.
Interestingly, the TOCSY 13C labeling patterns of fatty acyl chains at the ester end – 
C4H2-C3H2-C2H2-C1O2 in 13C8-octanoate-treated ZR75-1 cells could not be simply 
accounted for by direct incorporation or incorporation of the β-oxidation product (13C2-
acetyl CoA) of this fatty acid into lipids. As shown in Fig. 8D, the 13C satellite cross-peak 
patterns of H2 (peak 11) and H3 (peak 16) (Lane and Fan 2007, Lane, Fan et al. 2009) 
revealed not only 13C2-13C3- ( ) but also 13C2-12C3 ( ) and 12C2-13C3 ( )-fatty acyl 
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chains. These labeling patterns were similarly observed for H3 and H4 (not shown). 
With 13C8-octanoate as the fatty acyl precursor for lipid synthesis, we would expect 
uniform 13C labeling at C2-4 of fatty acyl chains via direct incorporation, which was 
inconsistent with the 1H TOCSY data. The 13C2-12C3 and 12C2-13C3-fatty acyl isotopomers 
could be derived from 13C labeled acetyl CoA via the de novo fatty acid synthesis pathway 
in which octanoate-derived AcCoA mixes with an unlabeled pool of AcCoA, 
producing 12C112C213C313C4, 13C113C212C312C4 as well as all 13C, and similarly for the 
terminal carbons. This then implicated β-oxidation of 13C8-octanoate into 13C2-AcCoA. The 
pattern for C3,C4 however, requires that singly labeled AcCoA is present, which may be 
derived via the Krebs cycle and malic enzyme activity (Figure 9).
The fractional enrichment at the C2,3,4 positions of fatty acyl chains derived from 13C8-
octanoate (30%) was significant relative to that derived from 13C6-glucose (60%), indicating 
that exogenous fatty acids are good substrates for complex lipid biosynthesis, as has been 
shown for other cancer cells (Kamphorst, Cross et al. 2013). However, it would be difficult 
to quantitatively compare the contribution of scavenged exogenous 13C8-octanoate relative 
to 13C6-glucose to lipid metabolism with the present data due to lack of knowledge on their 
respective contribution to β-oxidation.
The same sets of lipid extracts from Fig. 7 were also analyzed by FT-ICR-MS for 13C 
isotopologues of various lipid species. While NMR analysis provided information on the 13C 
positional isotopomers of lipids as a whole, it cannot distinguish the labeling patterns of 
individual phospholipids. With the high-resolution and accurate mass capability of FT-ICR-
MS, a large number of lipids and their 13C isotopologue distribution can be obtained directly 
from crude lipid extracts (Lane, Fan et al. 2009, Higashi 2011).
As shown in Figure 10A, the FT-ICR-MS profiling of lipidic extracts of HMEC, MCF-7, 
and MDAMB-231 cells showed distinct lipid isotopologue distributions for a number of 
lipid species. The expanded spectral region denoted by the blue box (Fig. 10B) illustrated in 
details the 13C isotopologue distribution of PC[32:1] (phosphatidyl choline with 32 total 
acyl carbons and 1 unsaturation site), where the 13C3 isotopologue (m3, m/z 735.568128) 
along with those containing even (meven) and odd (modd) numbers (up to 28) of 13C were 
evident while the monoisotopic or all 12C (m0) species was absent. This indicated that most 
of the cellular inventory of PC[32:1] had turned over in all three cell lines. As we have 
shown previously (Lane, Fan et al. 2009), the m3, meven, and modd isotopologues correspond 
to glycerolipids with 13C3-glycerol backbone only, 13C2n-fatty acyl chains, and 13C3-
glycerol backbone+13C2n-fatty acyl chains when cells are grown in 13C6-glucose. The 
isotopologue distributions of this lipid are quite different in the three cell lines, and overall 
lower 13C incorporation in MDA-MB-231 than in either MCF-7 or HMEC (Fig. S3), which 
is consistent with the NMR data (Fig. 7).
Similarly, the red box region in Fig. 10C displayed the 13C isotopologues assigned to PS-
pmg 40:7 +H (MDAMB-231). The m0 (820.548398 m/z) is at the base of prominent peak 
(labeled 820.62431 m/z). Up to m11 its isotopologues are at the base of the labeled peaks, or 
not visible at this scale. Starting at 832.58805 m/z, the prominent peaks are the 
isotopologues. MCF7 is PE 40:7 +Na. The m0 (812.513658 m/z) is at the base of the 
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prominent peak (unlabeled). Up to m19 the isotopologues are at the base of the labeled 
peaks, or not visible at this scale. Starting at 832.58660 m/z, the prominent peaks are the 
isotopologues. HMEC is PC-pmg 40:7 +H. The m0 (818.602868 m/z) was not detected. Up 
to m15 the isotopologues are at the base of the labeled peaks, or not visible at this scale. 
Starting at 834.66458 m/z, the prominent peaks are the isotopologues.
3.5 Metabolic activities traced by 13C6-glucose in mouse xenografts of ZR-75-1 and MDA-
MB-231 cells differed from those in vitro but the metabolic differences between the two cell 
xenografts recapitulate those in vitro
Cells in culture may differ metabolically from those in vivo due to the influence of 3D cell 
architecture and/or tumor microenvironment. We therefore performed SIRM analysis in 
orthotopic mouse xenografts of ZR75-1 and MDAMB-231 cells for comparison with those 
in vitro. Figure 11A shows representative 1D 1H{13C}-HSQC spectra of extracts from the 
xenografts of the two cell lines with 13C6-glucose introduced as bolus injections via the tail 
vein (Lane, Yan et al. 2015). The xenografts of the two cell lines showed large metabolic 
differences (Fig. 11A), e.g. abundance of 13C-lactate (Lac), -Gln, and -glycogen was 
enhanced in the ZR75-1 over MDAMB-231 xenografts, while that of 13C-Ala, -Glu, 
succinate, -Asp, -Gly, as well as the ribosyl subunit of AXP and UXP showed the opposite 
trend. These data were consistent with heightened glycolysis and glycogen metabolism but 
reduced Krebs cycle, Gly synthesis, as well as PPP and/or nucleotide biosynthesis in ZR75-1 
versus MDAMB231 tumors (Figure 11B, Table 2). These metabolic differences in the two 
tumor xenografts largely recapitulated those in the corresponding cell lines in vitro (Fig. 
11B, Table 2). On the other hand, there were large differences between in vivo and in vitro 
glucose metabolism in individual cell lines. For example, the abundance ratios among 13C-3-
lactate, 13C-1′-AXP, 13C-1′-UXP, and 13C-4-Glu were dramatically different between in 
vivo and in vitro conditions for both ZR75-1 (cf. black lines in Fig. 11A,B) and 
MDAMB-231 (cf. red lines in Fig. 11A,B) cells. These differences presumably reflect the 
influence of tumor architecture or TME on tumor cell metabolism.
4. Discussion
The breast cancer cells investigated had wildly different growth rates in culture with 
doubling times ranging from 18–20 h for the aggressive triple negative MDA-MB-231 to 80 
h for the estrogen sensitive ZR75-1 line (cf. Table 1). The rate of cell growth is determined 
by numerous factors, but a common requirement for cell doubling is the uptake of different 
nutrients to support both energetic and anabolic demands from growth such as 
macromolecular biosynthesis. Here, we demonstrated the use of different 13C-labeled 
substrates coupled with NMR and FT-ICR-MS analysis to probe the fate of these substrates 
in a primary breast and three breast cancer cell lines varying in growth rates. The 
methodologies revealed the differential fate of various substrates transformed through 
central metabolic pathways that are essential for energy and biomass production. Although 
preliminary, the findings suggested some notable aspects of breast cancer cell metabolism 
for further investigations.
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For example, glycolytic capacity as estimated from 13C6-glucose-derived lactate production 
and release to the media (Table 2), did not appear to be always the key to determining the 
rate of breast cancer cell proliferation, as ZR75-1 cells had higher capacity than the faster 
growing MCF-7 and MDAMB-231 cells (cf. Tables 1,2). Similar observations have 
previously been reported in other systems (Jain M, Nilsson R et al. 2012, Dolfi, Chan et al. 
2013). It should be noted that the medium lactate production was a proxy measure of 
glycolytic capacity, and did not take into account the contribution of intracellular fates of 
glycolytic pyruvate, although the latter constitutes only a small fraction of the total pyruvate 
derived from glucose in cancer cells (data not shown; (Fan, Kucia et al. 2008, Le, Lane et al. 
2012, Dong, Yuan et al. 2013).
We also found that glucose was by far the preferred source of nucleotide ribose produced via 
PPP in the breast cancer cell lines studied, as the 13C enrichment in the ribose subunit of the 
free nucleotide pool was high with 13C6-glucose as the source. Breast cancer cells (MDA-
MB-231 and MCF-7) appeared to favor ribose synthesis via the oxidative branch of PPP, 
thereby leading to more NADPH production, relative to the primary HMEC cells. Different 
types of cells use widely different ratios of the oxidative and non-oxidative branches of the 
PPP from mainly oxidative (Lee, Boros et al. 1998, Centelles, Ramos-Montoya et al. 2007, 
Yang, Lane et al. 2013) to almost completely non-oxidative (Boros, Puigjaner et al. 1997, 
Ying, Kimmelman et al. 2012) or more evenly balanced (Boren, Cascante et al. 2001, Vizan, 
Boros et al. 2005, Kominsky, Klawitter et al. 2009).
Although anaplerosis (e.g. pyruvate carboxylation (Sellers, Fox et al. 2015) and 
glutaminolysis (DeBerardinis and Cheng 2010, Ochoa-Ruiz and Diaz-Ruiz 2012) is 
expected to be activated in cancer cells due to growth demand, PC activation appeared to be 
more closely associated with breast cancer cells than enhanced glutaminolysis, as the latter 
fueled uracil ring synthesis more extensively in HMEC than MCF-7 cells (cf. Table 4). This 
is consistent with a recent report that PC was overexpressed in cancerous versus non-
cancerous breast cells (Phannasil, Thuwajit et al. 2015). Glutaminolysis also appeared to be 
an insignificant source for phospholipid biosynthesis in breast cancer or primary breast cell 
lines but glucose, glycerol and octanoate were good substrates for new membrane lipid 
production. We further noted that phospholipid synthesis from octanoate appeared to be 
substantially mediated via β-oxidation, as opposed to direct incorporation via acyl chain 
elongation. Although contorted, the βoxidation route could serve the purpose of generating 
energy and reducing equivalents, which are also required for lipid synthesis, in addition to 
producing the acetyl CoA precursor for the synthesis of fatty acyl chains. Finally, glucose 
transformations through the central pathways in ZR75-1 or MDAMB-231 cells appeared to 
be influenced by the tumor architecture or microenvironment but the metabolic distinctions 
between the two cell lines appeared to be maintained from in vitro cultures to in vivo 
xenografts.
5. Conclusions
In conclusion, by employing different stable isotope tracers and stable isotope-resolved 
metabolomics (SIRM) approaches, we demonstrated the differential use of 13C6-
glucose, 13C-1/2-glucose, 13C5,15N2-Gln, 13C3-glycerol, and 13C8-octanoate by different 
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human breast cell lines via glycolysis, PPP, the Krebs cycle, nucleotide biosynthesis, and 
lipid turnover pathways. Although preliminary, we found that glycolysis was not strongly 
associated with the rate of breast cancer cell proliferation, glutaminolysis did not support 
lipid synthesis in primary breast or breast cancer cells but contributed extensively to 
pyrimidine ring synthesis in all cell types, anaplerotic pyruvate carboxylation was activated 
in breast cancer versus primary cells, and glucose metabolism in individual breast cancer 
cell lines could be influenced by tumor architecture/microenvironment but not the metabolic 
distinctions between the cell lines.
The quantitative metabolic differences between cell lines are very clear also in the orthotopic 
xenografts. The uptake and utilization of glucose and glutamine is quantitatively different in 
the two xenografts. The metabolic reprogramming that occurs indicates that there may be 
multiple solutions to the demands of cell proliferation. In these studies we have shown that 
ER+ and triple negative cells have quite different metabolic phenotypes.
Supplementary Material
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Highlights
• Nutrient utilization in different breast cancer cell lines is determined by stable 
isotope resolved metabolomics
• There are clear metabolic differences between estrogen – dependent and triple 
negative cell lines, especially in lipid synthesis
• Differences in metabolic phenotypes are recapitulated in orthotopic mouse 
xenografts.
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Figure 1. Carbon fates in central metabolism
Observed fates of glucose and glutamine-derived carbon in breast cancer cells. The inner 
dashed box represents mitochondrial reactions. 1 glucose transporter; 2 hexokinase; 3 
phosphoglucomutase; 4 aldolase; 5 lactate dehydrogenase; 6 alanine amino transferase; 7 
glucose/hexosamine pathway; 8 pentose phosphate pathway: oxidative branch; 9 pentose 
phosphate pathway: non-oxidative branch ; 10, pyrimidine nucleotide synthesis; 11 
hexosamine pathway; 12 glycogen synthesis; 13 phosphoglycerate dehydrogenase; 14 
glycerol-3-phosphate dehydrogenase 15 pyruvate dehydrogenase; 16 pyruvate carboxylase; 
17 citrate synthase; 18, 18′ malate dehydrogenase; 19,19′ aspartate aminotransferase; 20 
malic enzyme; 21 glutaminase; 22 ATP-dependent citrate lyase; 23 fatty acid synthesis; 24 
purine biosynthesis.
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Figure 2. 2D 1H TOCSY Spectra of four breast cell lines grown in the presence of 13C6-glucose 
show differential capacity for ribose incorporation into nucleotides
TCA extracts were prepared from cells grown for 24 h in the presence of 13C6-glucose. 2D 
TOCSY contour maps were shown along with the corresponding 1D high-resolution 1H 
spectra. Dashed boxes delineate 13C satellite cross-peaks for the H1′ (x-axis) to H2′ and 
H3′ (y-axis) in the ribosyl unit of adenine (AXP) and H1′ to H2/H3′ in the ribosyl unit of 
uracil (UXP) nucleotides. Such 13C labeling patterns are consistent with the presence 
of 13C5-ribose subunits in both types of nucleotides, which in turn suggests the operation of 
PPP via the oxidative and/or non-oxidative branches. Values in parenthesis denote 
fractional 13C enrichment in the ribosyl unit of AXP or UXP at the 1′ position. A. HMEC; 
B. MCF-7; C. ZR-75-1; D. MDA-MB-231
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Figure 3. 13C atom tracing of 13C-1+13C-2-glucose transformations via glycolysis, PPP, and 
nucleotide (NT) biosynthesis
TCA extracts were prepared from cells grown for 24 h in the presence of equimolar 13C-1- 
and 13C-2-glucose. ● denotes 12C while ,  represent 13C derived from OxPPP and 
NOxPPP, respectively. Ox PPP and NOx PPP: oxidative and non-oxidative branches of the 
pentose phosphate pathway, respectively; Glc: glucose; F6P: fructose-6-phosphate; GAP: 
glyceraldehyde-3-phosphate; Pyr: pyruvate; Lac: lactate; R5P: ribose-5-phosphate; X5P: 
xylulose-5-phosphate; Sed7P: sedoheptulose-7-phosphate; NXP: nucleotides; TK: 
transketolase; TA: transaldolase
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Figure 4. 2D 1H TOCSY Spectra of three breast cell lines grown in the presence of 13C-1-+13C-2-
glucose reveal differential capacity for oxidative and non-oxidative branches of the pentose 
phosphate pathway
TCA extracts were prepared from cells grown for 24 h in the presence of 13C-1-+13C-2 
glucose. 13C labeling patterns in the ribosyl subunits of nucleotides. These labeling pattern 
showed that both oxidative and non-oxidative branches of the PPP were active. Dashed lines 
indicated 13C satellite cross-peaks at given atomic positions of metabolites.
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Figure 5. 
13C tracing from 13C6-Glc or 13C5,15N2-Gln into uracil ring. The two sets of atom tracing 
depict the transformation of 13C6-Glc (A) or 13C5,15N2-Gln (B) into Asp via the first turn of 
the Krebs cycle, and then into the uracil ring of UMP via the pyrimidine synthesis pathway. 
●: 12C; : 13C from pyruvate dehydrogenase-initiated Krebs cycle in A or from 
glutaminolysis+Krebs cycle in B;  : 13C from pyruvate carboxylase-initiated Krebs cycle ; 
 : 13C from glutaminolysis+Krebs cycle+malic enzyme (Le, Lane et al. 2012); DHO : 
dihydroorotate.
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Figure 6. 13C incorporation from 13C6-glucose versus 
13C5,
15N2-Gln into pyrimidine nucleotides 
in three breast cell lines
Cells were grown for 24 h in the presence of 5 mM each labeled glutamine (A) or glucose 
(B) tracer. 2D TOCSY spectra were recorded at 600 or 800 MHz using a mixing time of 50 
ms along. The 2D TOCSY contour maps were shown along with the 1D high-resolution 1H 
spectra. Dashed boxes depicted the 13C satellites of C5 to C6 cross-peaks of the uracil ring 
in UXP with horizontal pairs, vertical pairs, and 4-corner satellites representing 13C labeling 
at C5, C6, and C5,6 of uracil, respectively.
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Figure 7. 
MDAMB-231 cells synthesize less lipids from glucose than other breast cell lines despite its 
higher proliferation rate. HMEC (A), MCF-7 (B) and MDA-MB-231 (C) cells were grown 
for 24 h in the presence of 13C6-glucose and extracted as described in the Methods. The lipid 
extracts were dissolved in d4-methanol, and TOCSY spectra were recorded at 14.1 T with an 
isotropic mixing time of 50 ms at 25 °C. Both HMEC (A) and MCF-7 (B) cells showed 
extensive 13C enrichment (as 13C satellite cross-peaks, green boxes) in the glycerol subunit 
and fatty acyl chains, which was less in extent for the glycerol subunit and absent for the 
fatty acyl chains in MDAMB-231 cells (C). Blue boxes denote covalent linkages of protons 
attached to 12C of the glycerol backbone and fatty acyl chains. 1/3, 2: 13C satellites, 12C-
attached unsaturated protons, respectively; 3, 4: 12C-attached, 13C satellite of H2 of glycerol 
backbone, respectively; 5, 6/7: 13C satellite,12C-attached H1 of glycerol backbone, 
respectively; 8/10, 9: 13C satellites, 12C-attached H3 of glycerol backbone, respectively; 11, 
12: : 13C satellites, 12C-attached H2 of fatty acyl chains, respectively; 13, 14: 12C-
attached, 13C satellite of H11 of fatty acyl chains, respectively; 15, 16: 12C-attached, 13C 
satellite of H3 of fatty acyl chains, respectively.
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Figure 8. Differential incorporation of carbon from different sources into phospholipids of 
ZR-75-1 cells
Cells were grown in the presence of 20% oxygen and 13C6-glucose (A), 13C5,15N2-
glutamine (B), 13C3-glycerol (C) or 13C8-octanoate (D) for 72 h, and extracted for 
phospholipids (PL) with methanol. The TOCSY spectra were recorded at 18.8 T, 20 °C. 
Blue and green boxes respectively denote 1H connectives between 12C-attached protons 
and 13C satellites of 13C-attached protons. See Fig. 7 for the assignment of each numbered 
peaks.
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Figure 9. 13C incorporation from 13C8-octonate into fatty acyl chains of lipids in ZR75-1 cells 
via beta-oxidation and malic enzyme activity
The 13C atom in 13C8-octanoate is traced into lipids via the reactions of β-oxidation, Krebs 
cycle, malic enzyme (ME), pyruvate dehydrogenase (PDH), ATP-citrate lyase (ACL), acetyl 
CoA carboxylase (ACC), and fatty acid synthase (FAS). Double dashed lines delineate 
mitochondria from the cytoplasm. OAA: oxaloacetate.
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Figure 10. FT-ICR-MS analysis of lipids extracted from three breast cell lines reveals distinct 
capacity of 13C6-glucose in fueling de novo lipid synthesis
Lipids were extracted from cells grown in the presence of 13C6-glucose and analyzed by FT-
ICR-MS as described in the Methods. A. the m/z range of MDAMB-231, MCF-7, and 
HMEC extracts dominated by diacylglycerophospholipids; B the expanded m/z range 
dominated respectively by is PC 32:1+H labeled in all 3 cell types. The prominent, labeled 
peaks are the isotopologues (blue box from A); C. expansion red box of panel A: 
assignments are as follows: MDA is PS-pmg 40:7 +H (820.548398 m/z for m0 ; MCF7 is PE 
40:7+Na -m0 (812.513658 m/z) is at the base of the prominent peak (unlabeled). HMEC is 
PC-pmg 40:7 +H. The m0 (818.602868 m/z) was not detected.
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Figure 11. 13C6-glucose transformations in ZR75-1 and MDAMB-231 cells as mouse xenografts 
show similar metabolic distinctions as observed in vitro
Orthotopic tumors were grown from ZR75-1 or MDAMB-231 cells as described in the 
Methods. Mice were treated with 20 mg each 13C6-glucose via three tail vein injections at a 
15-min interval (Lane, Yan et al. 2015). The tumors were harvested, polar metabolites 
extracted, and analyzed by 1D 1H{13C}-HSQC at 14.1 T and 20 °C in A. ZR75-1 and 
MDAMB231 cells in B were cultured in DMEM medium containing 0.1% 13C6-glucose for 
24 h before extraction of polar metabolites with 10% trichloroacetic acid (MDAMB231) or 
60% acetonitrile (ZR75-1) and 1D HSQC analysis as described in Methods. Some of the 
metabolites in B such as lactate (Lac), Ala, Glu, Asp, and adenine nucleotides (AXP) 
displayed different chemical shifts between the extracts of the two cell lines due to their pH 
difference.
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Table 1
Cells used for Stable Isotope Resolved Metabolomics (SIRM) analysis.
Cell Designation optimal [E2]/nM Doubling time/h Tumorigenic?
HMEC - 48 N
MDA-MB-231 - 18–20 Y
MCF-7 10 30 Y
ZR-75-1 80 80 Y
E2: 17-β-estradiol; HMEC: primary human mammary epithelial cells, MDA-MB-231: a triple negative breast carcinoma cell; MCF-7, ZR-75-1: 
estrogen-receptor positive breast carcinoma cells
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